Diseases & conditions

US Judge Stops Compounders From Making Ozempic Copies

Published APR 25 2025

Story

Above: An Ozempic pen. Image credit: Unsplash

The Facts

On Thursday, a federal judge in Texas rejected compounding pharmacies' attempt to continue producing copycat versions of Novo Nordisk's popular weight loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's (FDA) February decision that declared the shortage of these medications is over.
Reuters
CNBC
Novo Nordisk
Small-scale compounding pharmacies must immediately cease production of semaglutide (the active ingredient in Ozempic and Wegovy) copies, while larger federally licensed facilities have until May 22 to stop manufacturing.
CNBC
Fierce Pharma
The compounded versions of Ozempic and Wegovy typically cost around $200 monthly compared to brand-name drugs priced at approximately $500-1,300 per month without insurance coverage.
TODAY.com
NBC4 Washington
Novo Nordisk has filed 111 lawsuits across 32 states against entities that it claims are "unlawfully marketing and selling compounded semaglutide," including drugs that "pose significant risks to patient safety."
Reuters
Prnewswire
As of Feb. 28, the FDA has received over 455 adverse event reports related to compounded semaglutide, including dosing errors by patients or healthcare professionals.
Independent
Health
The ruling follows a similar decision earlier this year that stopped compounders from producing versions of Eli Lilly's Mounjaro and Zepbound. On Wednesday, the drugmaker sued four telehealth firms for allegedly selling illegal copies of the drug made by compounding pharmacies.
Newsnationnow
Wired
Bloomberg Law

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

The FDA's decision to halt compounded versions protects patient safety and upholds quality standards, as these copycat drugs bypass crucial regulatory oversight and may pose serious health risks. The shortage is genuinely over; patients should only use FDA-approved medications that have undergone rigorous testing and manufacturing controls.

FDA

Narrative B

Millions of patients who cannot afford brand-name medications will lose access to life-changing, more accessible treatment options. The FDA acted prematurely in declaring the shortage over, and ending compounding will worsen supply issues while forcing desperate patients to seek potentially dangerous counterfeit drugs online.

The New York Times

Narrative C

Pharmaceutical patents grant monopolies that prioritize profit over people. Life-saving drugs become unaffordable, delaying or denying care to millions. Innovation shouldn't come at the cost of human lives. The current patent system stifles competition, inflates prices, and deepens inequality — turning medicine into a privilege, not a right. Health should never be a commodity.

R Street Institute